These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 2905529)

  • 21. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
    Boyson SJ; McGonigle P; Luthin GR; Wolfe BB; Molinoff PB
    J Pharmacol Exp Ther; 1988 Mar; 244(3):987-93. PubMed ID: 2908050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?
    Crow TJ; Cross AJ; Johnstone EC; Owen F; Owens DG; Waddington JL
    J Clin Psychopharmacol; 1982 Oct; 2(5):336-40. PubMed ID: 7130435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
    Seeman P; Guan HC; Van Tol HH; Niznik HB
    Synapse; 1993 Aug; 14(4):247-53. PubMed ID: 8248849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Specific binding of 3H-domperidone--a selective ligand of D2-dopamine receptors--by the human caudate nucleus].
    Zlobina GP; Chekalina ND
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(7):1043-5. PubMed ID: 2960110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia.
    Dean B; Pavey G; Scarr E; Goeringer K; Copolov DL
    Life Sci; 2004 May; 74(25):3115-31. PubMed ID: 15081577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.
    Wong DF; Wagner HN; Tune LE; Dannals RF; Pearlson GD; Links JM; Tamminga CA; Broussolle EP; Ravert HT; Wilson AA; Toung JK; Malat J; Williams JA; O'Tuama LA; Snyder SH; Kuhar MJ; Gjedde A
    Science; 1986 Dec; 234(4783):1558-63. PubMed ID: 2878495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies.
    Haraguchi K; Ito K; Kotaki H; Sawada Y; Iga T
    Drug Metab Dispos; 1997 Jun; 25(6):675-84. PubMed ID: 9193868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of molecular action of neuroleptics].
    de Erausquin GA
    Vertex; 2003; 14(51):36-44. PubMed ID: 12690408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The involvement of D-1 and D-2 dopamine receptors in the effects of neuroleptics and the pathogenesis of schizophrenia].
    Wielgosz M
    Psychiatr Pol; 1992; 26(5):357-64. PubMed ID: 1363827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoamines and schizophrenia.
    Sedvall G
    Acta Psychiatr Scand Suppl; 1990; 358():7-13. PubMed ID: 1978495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevation of brain neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Am J Psychiatry; 1980 Feb; 137(2):191-7. PubMed ID: 6101525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
    Butler B; Bech P
    Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The dopamine hypothesis of schizophrenia. New findings for an old theory].
    Heinz A
    Nervenarzt; 2000 Jan; 71(1):54-7. PubMed ID: 10695033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neurotensin, dopamine and mode of action of neuroleptics].
    Tassin JP
    Encephale; 1989; 15(5):465-70. PubMed ID: 2574102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropharmacology of tics.
    Fog R; Regeur L
    Rev Neurol (Paris); 1986; 142(11):856-9. PubMed ID: 2881341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.
    Farde L; Wiesel FA; Nordström AL; Sedvall G
    Psychopharmacology (Berl); 1989; 99 Suppl():S28-31. PubMed ID: 2573104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.
    Sanyal S; Van Tol HH
    J Psychiatr Res; 1997; 31(2):219-32. PubMed ID: 9278187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New antipsychotic agents and the future.
    Mackay AV
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):51-3. PubMed ID: 2858482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.